CARGO Therapeutics, Inc. (NASDAQ: CRGX) recently disclosed key updates regarding its strategic direction, workforce, and financial impacts. The company’s Board of Directors greenlit a decision to ...

The majority are in the very early preclinical stage of development, but applications for regulatory approval have been ...

Toronto, meanwhile, does not have a dedicated department or officer devoted to tackling the city’s booming rat problem, which a new study found was the third-fastest growing of 16 major cities. The ...

While the company is prioritizing RJVA-001 and a lead program in obesity, it's pausing some R&D efforts and laying off 17 percent of its workforce.

NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

CAR T–focused biotech Cargo Therapeutics surprised and disappointed analysts when it announced that it would discontinue a ...

Hyderabad: The Supreme Court's decision to abolish the domicile or residence-based reservation for NEET (PG) has drawn mixed ...

The changes will extend the company's cash runway, enabling it to advance a tri-specific CAR T-cell candidate and its allogeneic cell therapy platform.

As whistleblower Edward Snowden said about his deep dive through U.S. intelligence databases in search of the conspiracy ...

CARGO Therapeutic announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 ...

Conspiracies that have a strong following but divide Shasta County resurfaced again at a public Board of Supervisors meeting.

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...